AC Immune (ACIU) said Wednesday that the US Food and Drug Administration has issued a Fast Track Designation for the PI-2620 Tau positron emission tomography, or PET, imaging agent that the company is developing with privately held Life Molecular Imaging to diagnose three neurodegenerative conditions, including Alzheimer's disease.
The Fast Track Designation also covers PI-2620 as a potential diagnostic for progressive supranuclear palsy and corticobasal degeneration, AC Immune said.
PI-2620 is in phase 3 clinical development for detecting Tau pathology in Alzheimer's disease and could eventually be adapted also for non-Alzheimer tauopathies such as progressive supranuclear palsy and corticobasal syndrome, the company said.
AC Immune rose nearly 2% in early trading Wednesday.
Price: 3.1200, Change: +0.06, Percent Change: +1.96
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。